Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Non-diabetic Nephropathy With Hypertension
Conditions
Non-diabetic Nephropathy With Hypertension
Trial Timeline
Dec 1, 2007 → Aug 1, 2009
NCT ID
NCT00573430About Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg
Candesartan Cilexetil + Candesartan Cilexetil + Candesartan Cilexetil 32mg is a approved stage product being developed by AstraZeneca for Non-diabetic Nephropathy With Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT00573430. Target conditions include Non-diabetic Nephropathy With Hypertension.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00573430 | Approved | Completed |
Competing Products
3 competing products in Non-diabetic Nephropathy With Hypertension
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Qutenza + Pregabalin | Astellas Pharma | Approved | 85 |
| Aliskiren + Placebo to Aliskiren + Hydrochlorothiazide (HCTZ) + Placebo to Hydrochlorothiazide (HCTZ) + Ramipril | Novartis | Phase 2 | 52 |
| Finerenone (BAY94-8862) + Placebo | Bayer | Phase 3 | 74 |